Comparing olanzapine with inactive drug for loss of appetite
- Conditions
- Health Condition 1: C00-D49- Neoplasms
- Registration Number
- CTRI/2023/09/057403
- Lead Sponsor
- Jefrilla Nancy J
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Histologically/cytologically confirmed case of cancer
Anorexia in a patient with cancer having VAS score <4 Appetite
1.Patients with known allergy to olanzapine
2.Patients with history of inability to tolerate olanzapine
3. Patients undergoing treatment either with chemotherapy, radiotherapy or surgery within 4 weeks of time before intiation of study
4.Patients on enteral feeding like Nasogastric,nasojejunal,PEG tubes
5.Patient with dysphagia or gastro intestinal obstruction
6.Patient with history of use of Megesterol Acetate/corticosteroids in previous 4 weeks
7.Patients already on statins and or oral/injectable hypoglycemic drugs
8.Patients with a known psychiatric disorder and taking anti psychotics
9.Patient is mentally incapacitated or has a severe emotional or psychiatric disorder, that in the opinion of the study investigator, precludes study entry
10.Patients not consenting for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the effect of olanzapine on the appetie and compare it with placeboTimepoint: 4 weeks
- Secondary Outcome Measures
Name Time Method To compare the body weight and BMI of both the study arm <br/ ><br>To assess other symptoms using R-ESAS in both arms <br/ ><br>Timepoint: 4 weeks